MR-guided Laser Interstitial Thermal Therapy (MRgLITT) for treatment of epileptogenic zones for Adults with refractory focal epilepsy

Tender description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England Specialised Commissioning (referred to as the Commissioner), invited suitably qualified and experienced providers to bid for an opportunity to provide MR-guided Laser Interstitial Thermal Therapy (MRgLITT) for treatment of epileptogenic zones for adults with refractory focal epilepsy (Lot 1: North & Lot 2: South). As a result of this procurement exercise the Commissioner has awarded contracts for these services. Lot 1: A. Lot 1- North MRgLITT, also known as ‘laser interstitial thermal therapy’ (LITT), is a minimally invasive treatment which can be used in focal refractory epilepsy. Stereotactic neurosurgical technique is used to guide a 3mm diameter fibreoptic laser to the target area of the brain. Under continuous MRI monitoring, laser energy is applied to the target area to destroy the part of the brain causing seizure activity. It is safer than open neurosurgery as there is less risk of collateral damage to other structures in the brain. Open surgery causes damage along the operative pathway to access the part to be removed, which is mitigated by this minimally invasive approach.<br/><br/>The service will commence on 1st September 2024 and will run for a duration of 5 years (initial<br/>period). The Commissioner has the option to extend for up to a further 2 years making a<br/>possible maximum contract duration of 7 years. Lot 2: B. Lot 2 - South MRgLITT, also known as ‘laser interstitial thermal therapy’ (LITT), is a minimally invasive treatment which can be used in focal refractory epilepsy. Stereotactic neurosurgical technique is used to guide a 3mm diameter fibreoptic laser to the target area of the brain. Under continuous MRI monitoring, laser energy is applied to the target area to destroy the part of the brain causing seizure activity. It is safer than open neurosurgery as there is less risk of collateral damage to other structures in the brain. Open surgery causes damage along the operative pathway to access the part to be removed, which is mitigated by this minimally invasive approach.<br/><br/>The service commenced on 23rd July 2024 and will run for a duration of 5 years (initial<br/>period). The Commissioner has the option to extend for up to a further 2 years making a<br/>possible maximum contract duration of 7 years.